TN-LUBRIZOL
30.4.2024 14:43:34 CEST | Business Wire | Press release
Eastman and Lubrizol have successfully partnered on improving adhesion strength of thermoplastic elastomers (TPEs) overmolded onto Eastman Tritan™ copolyester TX1501HF. The collaboration stemmed from a mutual recognition of overmolding's importance in manufacturing while delivering improved product performance and aesthetics in consumer goods when using Eastman’s sustainable material, Tritan™ Renew, and Lubrizol’s ESTANE® ECO, renewably sourced TPU.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430342572/en/
Eastman and Lubrizol collaborate to enhance TPE overmolding adhesion with sustainable materials. (Photo: Business Wire)
The companies researched how specific processing variables impact the adhesion strength of overmolded samples produced through 2K injection molding. The study’s findings are believed to be applicable across various TPE and substrate combinations. This is of particular interest when mechanical interlocks cannot be used, and material changes are not feasible but improvements in adhesion strengths are desired.
By optimizing key TPE processing variables like mold temperature, pack and hold time, and TPE barrel temperature, the research team achieved a notable 124% improvement in adhesion strength compared to values obtained using non-ideal processing conditions. An additional improvement in adhesion strength was observed when Lubrizol’s ESTANE® ECO 12T80E and 16T85 TPU grades were used. These grades displayed the highest peel strength values (> 310 N) of all TPEs evaluated in this preliminary study.
“This was a unique opportunity for two leading material companies to leverage sustainable multi-material solutions that enable customer innovations and expand the limits of consumer product experiences,” said Vince Haas, Lubrizol’s engineered polymers senior business director.
“This effort has advanced our understanding of overmolding and TPEs, providing valuable guidance for engineers and manufacturers looking to improve overmolded product strength,” said Courtland Jenkins, Eastman’s commercial director for engineered solutions. “These findings open doors for new and innovative product designs, particularly when using recycled content.”
For a detailed view of the study, access the white paper [link].
NPE2024 attendees are invited to visit Lubrizol’s booth #S35017, May 6-10 in Orlando, Fla., to see Tritan™ Renew materials overmolded with ESTANE® ECO technology and can also gain deeper insights through a joint webinar hosted by UL Prospector at 9 a.m. on Wednesday, June 12. Webinar registration link here [link].
About Eastman
Eastman is a global specialty materials company that produces a broad range of products found in items people use every day. With the purpose of enhancing the quality of life in a material way, Eastman is committed to safety, innovation and sustainability. Headquartered in Kingsport, Tennessee, USA, it had 2023 revenues of approximately $9.2 billion. For more information, visit www.eastman.com.
About The Lubrizol Corporation
The Lubrizol Corporation, a Berkshire Hathaway company, is a specialty chemical company whose science delivers sustainable solutions to advance mobility, improve wellbeing and enhance modern life. Founded in 1928, Lubrizol owns and operates more than 100 manufacturing facilities, sales and technical offices around the world and has more than 8,000 employees. For more information, visit www.Lubrizol.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430342572/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
